Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Inhibrx Biosciences, Inc. (INBX) had Stock-Based Compensation of $2.65M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-33.44M |
|
-- |
|
-- |
|
$30.93M |
|
$-30.93M |
|
$-2.51M |
|
$-33.44M |
|
$-33.44M |
|
$-33.44M |
|
$-33.44M |
|
$-33.44M |
|
$-33.44M |
|
$-30.93M |
|
$-30.39M |
|
15.59M |
|
15.59M |
|
$-2.15 |
|
$-2.15 |
|
| Balance Sheet Financials | |
$171.34M |
|
$3.20M |
|
$12.63M |
|
$183.97M |
|
$26.51M |
|
$174.99M |
|
$178.49M |
|
$205.00M |
|
$-21.04M |
|
$-21.04M |
|
$-21.04M |
|
14.61M |
|
| Cash Flow Statement Financials | |
$-38.03M |
|
$0.00M |
|
$75.46M |
|
$124.22M |
|
$161.66M |
|
$37.44M |
|
|
Stock-Based Compensation |
$2.65M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.46 |
|
-- |
|
-- |
|
1.14 |
|
-8.32 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-38.03M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
158.98% |
|
158.98% |
|
-18.18% |
|
-21.72% |
|
$-1.44 |
|
$-2.44 |
|
$-2.44 |
|